Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06MHZ
|
|||
| Former ID |
DIB003673
|
|||
| Drug Name |
NLG919
|
|||
| Synonyms |
NLG919; 1402836-58-1; 1-cyclohexyl-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethanol; NLG 919; CHEMBL3629569; AK166956; 1-Cyclohexyl-2-(5H-imidazo-[5,1-a]isoindol-5-yl)ethanol; alpha-Cyclohexyl-5H-imidazo[5,1-a]isoindole-5-ethanol; 1-Cyclohexyl-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethan-1-ol; YTRRAUACYORZLX-UHFFFAOYSA-N; GTPL9019; SCHEMBL13280897; GDC0919; EX-A574; DTXSID20735206; MolPort-035-395-785; HMS3653M05; AOB87373; GDC 0919; NLG919(GDC-0919); 2588AH; RG6078; BDBM50126144; s7111; AKOS025287054; CS-3512; SB16495; ACN-028914; KS-0000062W
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [1] | |
| Company |
Newlink genetics
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H22N2O
|
|||
| Canonical SMILES |
C1CCC(CC1)C(CC2C3=CC=CC=C3C4=CN=CN24)O
|
|||
| InChI |
1S/C18H22N2O/c21-18(13-6-2-1-3-7-13)10-16-14-8-4-5-9-15(14)17-11-19-12-20(16)17/h4-5,8-9,11-13,16,18,21H,1-3,6-7,10H2
|
|||
| InChIKey |
YTRRAUACYORZLX-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1402836-58-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Immune checkpoint (ICH) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800039434) | |||
| REF 2 | Deal watch: Genentech dives deeper into the next wave of cancer immunotherapies. Nat Rev Drug Discov. 2014 Dec;13(12):879. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.